Krystal files for IPO to move gene therapies into clinic – FierceBiotech
FierceBiotech |
Krystal files for IPO to move gene therapies into clinic
FierceBiotech That gene therapy, KB103, is designed to treat dystrophic epidermolysis bullosa, a rare disease that makes the skin fragile and susceptible to blisters and tears. Krystal thinks it can improve outcomes in these patients, who currently only have … |
